Trial
NCT02626520
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Essentia Health
Collaborators
—
Condition
Ductal Adenocarcinoma of Pancreas
Intervention
Gemcitabine and nanoparticle albumin bound paclitaxel
Why stopped
Study team felt toxicity of study regimen outweighed potential benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-13